# MenB Vaccine Does Not Prevent Gonorrhea, New Research Finds
Scientists have found that the Meningitis B vaccine provides no protection against gonorrhea infections, contradicting earlier hopes that the shot could offer dual benefits for at-risk populations.
The meningococcal group B vaccine, commonly known as MenB, was developed to prevent invasive meningococcal disease. However, because the bacterium shares structural similarities with Neisseria gonorrhoeae, the pathogen responsible for gonorrhea, researchers theorized the vaccine might also shield recipients from sexually transmitted infections.
The new evidence challenges this assumption. Major study findings reveal that men receiving the MenB vaccine experienced no reduction in gonorrhea rates compared to unvaccinated controls. This discovery matters for public health officials and clinicians who considered recommending MenB as part of comprehensive STI prevention strategies for high-risk groups.
The research involved examining infection rates among vaccinated and unvaccinated populations over defined periods. Scientists tracked gonorrhea diagnoses to determine whether prior MenB vaccination correlated with lower infection rates. The data showed no such correlation.
This finding does not diminish MenB's importance for preventing meningococcal meningitis, particularly in young adults and college students where outbreaks occur. The vaccine remains effective for its intended purpose. Rather, the study clarifies that health professionals cannot rely on MenB to provide gonorrhea protection.
For disease prevention, gonorrhea still requires targeted interventions like condom use, regular screening, and prompt antibiotic treatment. As antibiotic-resistant gonorrhea strains emerge globally, the absence of a vaccine-based prevention approach underscores the urgency of developing new prevention strategies.
Clinicians working with at-risk populations should continue recommending MenB for meningococcal protection